Summary. Ciprofloxacin, unlike nalidixic acid, can kill Escherichia coli cells in the absence of synthesis of protein or RNA. Hence, chloramphenicol or rifampicin do not abolish the bactericidal activity of ciprofloxacin against wild-type E. coli. Protein and RNA synthesis were not required for the bactericidal activity of ciprofloxacin against nalB, nalC and nalD mutants of E. coli. However, the addition of chloramphenicol or rifampicin abolished the bactericidal activity of ciprofloxacin against a nalA mutant in nutrient broth. It is concluded that the ability of ciprofloxacin to kill E. coli in the absence of protein or RNA synthesis involves the A subunit of DNA gyrase.
Introduction
The 4-quinolones appear to act on DNA gyrase, the bacterial enzyme that introduces negative supercoils into DNA.' Mutations affecting either the A or B subunits of this enzyme alter bacterial susceptibility to the 4-q~inolones.~ Shen et aL3 have proposed that, rather than acting directly on DNA gyrase, the drugs bind to saturable sites on supercoiled DNA. This binding is suggested to be facilitated by DNA gyrase.
The molecular events leading to the death of bacteria exposed to the 4-quinolones are not known. However, differences have been observed amongst these drugs in the conditions required for their lethal action. Protein and RNA synthesis are essential for the bactericidal activity of the older 4-quinolones, such as nalidixic On the other hand, some fluoroquinolones kill bacteria in the absence of protein or RNA ~ynthesis.~-~ This observation has led to the suggestion that these fluoroquinolones exert an extra bactericidal mechanism, termed B, in addition to that termed A, exhibited by nalidixic acid. Mechanism A requires protein and RNA synthesis as well as cell division495 but mechanism B, which is possessed by ciprofloxacin,6 DR-3355,7 fleroxacin,' lomeflo~acin,~ ofloxacin6 and pefloxacin' does not require these activities, and allows the killing of non-dividing bacteria. The basis of mechanism B is unknown but has been suggested by Dalhoff" to involve the bacterial membrane, rather than DNA gyrase.
In the present study, the bactericidal mechanisms of ciprofloxacin were determined for various mutants of E. coli KL16 that had altered susceptibility to 4-quinolones. The aim was to determine whether mechanism B could be abolished by specific mutations. Four different mutations were investigated : the nalA (gYrA) mutation, which causes an alteration in the A subunit of DNA gyrase;" the nalB mutation, which causes a reduction in permeability;" the nalC mutation, which alters the B subunit of DNA gyrase;I2 and the nalD mutation, which appears to alter both the B subunit and permeability. '
Materials and methods

Bacterial strains
E. coli KL16, a prototroph,' and its nalA," nalB," nalC (nal 31)l2 and nalD (nal 24)13 mutants were used. All the mutants were resistant to nalidixic acid. The nalA, nalB and nalD mutations increased the MIC of ciprofloxacin, whereas the nalC mutation reduced the MIC of the drug (table) . The strains were kept on nutrient-agar plates, which were subcultured every 10 days. Colonies taken from these plates were used to seed the overnight cultures for the experiments described below. 
An tibacterial preparation
150 mg/L) alone, or in combination with chloramphenicol, was determined in nutrient broth at 37°C after a 3-h exposure period. Bacteria were enumerated by serial dilution in nutrient broth followed by viable counting on nutrient agar, as described by Lewin et ,, 14 Ciprofloxacin (Bayer, UK) and chloramphenicol (Parke-Davis, UK) were dissolved in sterile distilled water. Ofloxacin (Hoechst UK) was dissolved in 0.5 M NaOH (0.02 ml/mg) before dilution in sterile distilled water. Rifampicin (Merrell DOW, UK) was dissolved in dimethylsulphoxide.
ui'
The rate of kill of bacteria treated with ciprofloxacin and ofloxacin alone, or in combination with rifampiAntibacterial activity of the 4-quinolones cin, in nutrient broth was derived from sequential viable counts determined at 30-min intervals over a The bactericidal activity of ciprofloxacin (0-15-4-h period, as described by Lewin and Smith." 
Results
100
Ciprofloxacin, at concentrations above the MIC, was bactericidal against the nalA, nalB, nalC and nalD mutants (figs. l a and b). Addition of a bacteriostatic concentration of the protein-synthesis inhibitor chloramphenicol20 mg/L reduced, but did not completely abolish, this activity against E. coli KL16, and the nalB, nalC and nalD mutants ( fig. 2) . On the other hand, chloramphenicol20 mg/L completely abolished the bactericidal activity of ciprofloxacin against the nalA mutant at concentrations up to 150 mg/L ( fig. 2) . Thus, ciprofloxacin was not bactericidal against the nalA mutant in the absence of protein synthesis.
The bactericidal activity of ciprofloxacin at its optimum bactericidal concentration (OBC, defined as the drug concentration giving the most rapid killing of the bacteria) was examined alone and in the presence of rifampicin, an inhibitor of RNA synthesis. At its OBC, ciprofloxacin was bactericidal against the parent E. coli strains and the mutants ( figs. 3-4) . Addition of a bacteriostatic concentration of rifampicin (160 mg/L) reduced, but failed to abolish, the bactericidal activity of ciprofloxacin against the nalB, nalC and nalD mutants, confirming that the 4-quinolone continued to exhibit mechanism B against these organisms ( fig. 4 and data not shown) . However, addition of a bacteriostatic concentration of rifampicin completely abolished the bactericidal activity of ciprofloxacin against the nalA mutant ( fig. 3) .
The bactericidal activity of ofloxacin, which also exerts mechanism B, was investigated against the four mutants. Rifampicin abolished the bactericidal activity of ofloxacin at its OBC against the nalA mutant but not against the nalB, nalC or nalD mutants. Hence, as with ciprofloxacin, ofloxacin could not kill the nalA mutant in the absence of RNA synthesis.
Discussion
Protein and RNA synthesis were found to be prerequisites for the mechanism B-dependent bactericidal activity of ciprofloxacin or ofloxacin against a nalA E. coli mutant. Mutations which affected the outer membrane (nalB) or the B subunit of DNA gyrase (nalC and nalD) and which altered bacterial sensitivity to the fluoroquinolones had no effect on the occurrence of mechanism B. Thus, the fluoroquinolones were bactericidal against nalB, nalC and nalD mutants, even when protein or RNA synthesis were inhibited. These data suggest that mechanism B involves the A subunit of DNA gyrase rather than the bacterial membrane, as has been suggested previously. l o It has been suggested16 that the possession of mechanism B explains why the frequencies of bacterial mutation to resistance to the fluorinated quinolones is much lower than to the non-fluorinated drugs such as nalixidic and oxolinic acids. 2 9 1 6-1 It was proposed' that two distinct mutations might be required to confer resistance to the fluoroquinolones whereas a single mutation would suffice for the older nonfluorinated drugs. However, the present data indicate that the nalA mutation abolishes mechanism B. In this context, it is interesting to note that although ofloxacin and ciprofloxacin both exhibit mechanisms A and B against S. rnarcescens,20 the frequency of mutation to resistance to the latter drug was higher than to the former.21*22 Hence, a low frequency of mutation resistance does not appear to be an inevitable correlate of possession of mechanism B by a drug. However, the possession of this additional bactericidal mechanism by the fluoroquinolones should still be advantageous as it enables these drugs to kill non-dividing bacteria. '-' Finally, we have recently reported that, in the absence of protein synthesis, ciprofloxacin is no longer able to kill E. coZi strains that have acquired 4-quinolone resistance during therapy.23 Thus, these isolates appear to have lost sensitivity to killing by mechanism B.23 As with the naZA mutant studied here, such isolates may have an alteration in the A
